El interés en corto de Vir Biotechnology da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Vir Biotechnology. Los datos de interés en corto se actualizan cada dos semanas.

Vir Biotechnology (NASDAQ:VIR) Bolsa, Informe de interés en corto

VIR BIOTECHNOLOGY INC

Vir Biotechnology

Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

Vir Biotechnology Inc

Viratech Corp

Neuralbase AI Ltd

Virco Manufacturing Corporation - Common Stock

Virco Manufacturing Corp

Viridien

Pacer Funds Trust BioThreat Strategy ETF

Virtu Financial, Inc. - Class A Common Stock

Virtu Financial Inc

VIRACTA THERAPEUTICS INC by Viracta Therapeutics, Inc.

Viracta Therapeutics Inc

Monday.Com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) reported quarterly earnings of $1.10 per share which beat the analyst consensus estimate of $0.70 by 57.14 percent. This is a 80.33 percent increase over earnings of $0.61 per share from the same period last year. The company reported quarterly sales of $282.25 million which beat the analyst consensus estimate of $275.78 million by 2.35 percent. This is a 30.12 percent increase over sales of $216.91 million the same period last year.

Earnings

Earnings Beats

News

MNDY

Monday.Com Q1 Adj. EPS $1.10 Beats $0.70 Estimate, Sales $282.25M Beat $275.78M Estimate

Blade Air Mobility (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLDE#NASDAQ">BLDE</a>) affirms FY2025 sales outlook from $245.00 million-$265.00 million to $245.00 million-$265.00 million vs $256.33 million estimate.

Guidance

BLDE

Blade Air Mobility Affirms FY2025 Sales Guidance of $245.00M-$265.00M vs $256.33M Est

Lightbridge (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTBR#NASDAQ">LTBR</a>) reported quarterly losses of $(0.24) per share. This is a 14.29 percent decrease over losses of $(0.21) per share from the same period last year.

LTBR

Lightbridge Q1 EPS $(0.24) Down From $(0.21) YoY

Superior Industries Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUP#NYSE">SUP</a>) reported quarterly losses of $(0.92) per share which missed the analyst consensus estimate of $(0.53) by 73.58 percent. This is a 22.67 percent decrease over losses of $(0.75) per share from the same period last year. The company reported quarterly sales of $321.60 million which beat the analyst consensus estimate of $300.49 million by 7.03 percent. This is a 1.68 percent increase over sales of $316.30 million the same period last year.

Earnings Misses

Superior Industries Intl Q1 EPS $(0.92) Misses $(0.53) Estimate, Sales $321.60M Beat $300.49M Estimate

Essential Utilities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTRG#NYSE">WTRG</a>) affirms FY2025 GAAP EPS guidance from $2.07-$2.11 to $2.07-$2.11 vs $2.10 analyst estimate..

WTRG

Essential Utilities Affirms FY2025 GAAP EPS Guidance of $2.07-$2.11 vs $2.10 Est

Blade Air Mobility (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLDE#NASDAQ">BLDE</a>) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.11) by 63.64 percent. This is a 33.33 percent increase over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $54.31 million which beat the analyst consensus estimate of $49.43 million by 9.86 percent. This is a 5.42 percent increase over sales of $51.51 million the same period last year.

Blade Air Mobility Q1 EPS $(0.04) Beats $(0.11) Estimate, Sales $54.31M Beat $49.43M Estimate

Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.04) by 75 percent. This is a 150 percent decrease over earnings of $0.02 per share from the same period last year. The company reported quarterly sales of $21.77 million which beat the analyst consensus estimate of $19.20 million by 13.41 percent. This is a 11.17 percent decrease over sales of $24.51 million the same period last year.

HBIO

Harvard Bioscience Q1 Adj. EPS $(0.01) Beats $(0.04) Estimate, Sales $21.77M Beat $19.20M Estimate

Essential Utilities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTRG#NYSE">WTRG</a>) reported quarterly earnings of $1.03 per share which beat the analyst consensus estimate of $0.79 by 30.38 percent. This is a 6.19 percent increase over earnings of $0.97 per share from the same period last year. The company reported quarterly sales of $783.63 million which beat the analyst consensus estimate of $701.90 million by 11.64 percent. This is a 28.03 percent increase over sales of $612.07 million the same period last year.

Essential Utilities Q1 EPS $1.03 Beats $0.79 Estimate, Sales $783.63M Beat $701.90M Estimate

HC Wainwright &amp; Co. analyst Matthew Caufield reiterates Surrozen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRZN#NASDAQ">SRZN</a>) with a Buy and maintains $32 price target.

Price Target

Reiteration

Analyst Ratings

SRZN

HC Wainwright & Co. Reiterates Buy on Surrozen, Maintains $32 Price Target

U.S. District Judge Steven Logan has temporarily blocked the controversial transfer of federal land in Arizona to mining firms Rio Tinto (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIO#NYSE">RIO</a>) and BHP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHP#NYSE">BHP</a>). Logan cited the need for the <a target="_blank" href="https://www.benzinga.com/topic/u-s-supreme-court" rel="noreferrer noopener">U.S. Supreme Court</a> to deliberate on an appeal filed by Native American groups opposing the project.
The decision halts progress on the Resolution Copper project, a planned large-scale underground copper mine near Superior, Arizona. The project sits atop more than 40 billion pounds (18.1 million metric tons) of copper, a metal critical to electric vehicles and clean energy infrastructure. However, it also lies beneath Oak Flat, a site sacred to the San Carlos Apache people.
In an 18-page ruling, Judge Logan clarified the risk of irreparable harm to Apache religious rights if the land transfer were permitted before the Supreme Court makes its decision.
"It is abundantly clear that the balance of equities tips sharply in [Apache Stronghold's] favor," he wrote, according to Reuters. "They have established a likelihood of irreparable harm should the transfer proceed."
The project can potentially produce over 25% of anticipated domestic copper demand for several decades, but it would create a 3-kilometer-wide, 300-meter-deep crater, effectively destroying the Oak Flat site.
Logan dismissed Rio's arguments that their $2.7 billion investment and monthly maintenance costs of $11 million warranted urgency, stating these were a "voluntary choice."
The project's legal history is complex. Though Congress and then-President Barack Obama approved the land swap enabling the project in 2014, President Donald Trump moved to expedite the land transfer during his first term. President Joe Biden reversed that action, pending further court review. Yet Trump recently restarted the process, aiming for a final transfer by June 16, driving the emergency request that led to Logan's ruling.
If built, Resolution would be one of Rio Tinto's most significant future copper assets, offering decades of domestic supply at a time when the U.S. seeks to <a target="_blank" href="https://in.benzinga.com/25/02/43492445/critical-metal-demand-to-triple-by-2030-but-demographics-pose-risks" rel="noreferrer noopener">reduce reliance on mineral imports</a>. However, the project faces the same kind of local backlash that led to the halt of Rio Tinto's Jadar lithium project in Serbia.
Rio Tinto has been mitigating development risk through strategic partnerships. Today, it <a target="_blank" href="https://www.riotinto.com/en/news/releases/2025/rio-tinto-and-sumitomo-metal-mining-sign-definitive-agreement-for-winu-project-joint-venture" rel="noreferrer noopener">announced</a> a joint venture with Japan's Sumitomo Metal Mining to develop the Winu copper and gold project in Western Australia. Under the deal, Sumitomo will pay up to $430.4 million for a 30% stake, with $195 million upfront and further payments based on milestones.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45284809/barricks-world-class-mining-project-proceeds-as-planned-building-not-only-buying-ceo-says" target="_blank" rel="noreferrer noopener">Barrick's World-Class Mining Project Proceeds As Planned, ‘Building Not Only Buying' CEO Says</a></li>
</ul>
Photo by TimBrew via Shutterstock

Government

Large Cap

Regulations

Commodities

Asset Sales

Legal

Markets

Judge Halts Arizona Land Transfer To Rio Tinto Citing Native Appeal

Church &amp; Dwight Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHD#NYSE">CHD</a>) has signed a definitive agreement to acquire the Touchland&#xAE; brand for $700 million at closing, consisting of cash and Church &amp; Dwight restricted stock, and a payment up to $180 million contingent on the achievement of Touchland's 2025 net sales for a total purchase price of up to $880 million. Touchland is the fastest growing brand in the hand sanitizer category in the United States and is the #2 hand sanitizer in the category. The transaction, which is subject to customary closing conditions, is expected to close in the second quarter.
Touchland's net sales for the trailing twelve months through March 31, 2025 were approximately $130 million. The products are currently marketed in the U.S. and Canada and recently launched in the Middle East with Sephora.

Church & Dwight Agrees To Acquire Touchland Brand For $700M Plus Up To $180M Based On 2025 Sales

Invesco Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVZ#NYSE">IVZ</a>)1 today reported preliminary month-end assets under management (AUM) of $1,840.0 billion, a decrease of 0.3% versus previous month-end. The firm delivered net long-term inflows of $1.3 billion in the month. Non-management fee earning net outflows were $2.0 billion and money market net outflows were $12.1 billion. Unfavorable market returns decreased AUM by $1 billion. FX increased AUM by $9.2 billion. Preliminary average total AUM for the quarter through April 30 were $1,817.3 billion, and preliminary average active AUM for the quarter through April 30 were $1,027.3 billion.
 &nbsp;

Invesco's AUM Dips 0.3% to $1.84T, But Long-Term Inflows Hold Strong at $1.3B

Sally Beauty Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBH#NYSE">SBH</a>) lowers FY2025 sales outlook from $3.67 billion-$3.75 billion to $3.65 billion-$3.69 billion vs $3.72 billion estimate.

Sally Beauty Holdings Lowers FY2025 Sales Guidance from $3.67B-$3.75B to $3.65B-$3.69B vs $3.72B Est

Canaccord Genuity analyst Joseph Vafi maintains Blend Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLND#NYSE">BLND</a>) with a Buy and maintains $5.25 price target.

BLND

Canaccord Genuity Maintains Buy on Blend Labs, Maintains $5.25 Price Target

Macro Economic Events

WIIM

Economics

SPDR Dow Jones Industrial Average ETF Trust

Major indexes are higher after the US and China agreed to a temporary reduction in most tariffs on each other's goods.

CytomX Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>), a leader in the field of masked, conditionally activated biologic therapeutics, today announced the pricing of an underwritten offering of 76,923,076 shares of its common stock at an offering price of $1.30 per share, before underwriting discounts and commissions. All of the shares are being offered by the Company. The gross proceeds from the offering are expected to be approximately $100 million before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on May 13, 2025, subject to customary closing conditions.
The Company intends to use the net proceeds from this offering for research and development, general corporate purposes and working capital needs.

Offerings

CTMX

CytomX to Raise $100M in Stock Offering, Pricing 76.9M Shares at $1.30 Each

Somnigroup International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGI#NYSE">SGI</a>, ", Company", or ", Somnigroup", ))) today announced the launch of a secondary offering (the "Offering") of 15,376,743 shares of its common stock, par value $0.01 per share, by the former majority shareholder of Mattress Firm Group Inc., which shareholder is a subsidiary of IBEX Topco B.V. (the "Selling Stockholder"). All of the shares of common stock are being sold by the Selling Stockholder, and Somnigroup will not receive any of the proceeds from the Offering.
Goldman Sachs &amp; Co. LLC is acting as the sole underwriter for the Offering.

Somnigroup International Announces Secondary Offering Of 15.4M Shares At $0.01 Par Value By IBEX Subsidiary

Sally Beauty Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBH#NYSE">SBH</a>) sees Q3 sales of $918.782 million-$937.628 million vs $901.47 million analyst estimate.

Sally Beauty Holdings Sees Q3 Sales $918.782M-$937.628M vs $901.47M Est

Benchmark analyst David Williams maintains D-Wave Quantum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) with a Buy and raises the price target from $8 to $14.

QBTS

Benchmark Maintains Buy on D-Wave Quantum, Raises Price Target to $14

On May 6, 2025, the Board of Directors approved an extension of the share repurchase program for an additional four-year period ending on September 30, 2029. Under this extension, the Company is authorized to repurchase its common stock up to the amount remaining under the initial 2017 authorization, which is currently $501.1 million.

Buybacks

Sally Beauty Holdings Board Approves 4-Year Extension to $501M Share Buyback Program, Now Running Through 2029

Press Releases

Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC

Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta

Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results

Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025

Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study

Comments

Vir Biotechnology

Interés en corto

Vir Biotechnology (NASDAQ:VIR) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL